Peptides and combination of peptides for use in immunotherapy against various tumors

Patent metadata

Field	Value
Publication number	US-9802997-B2
Application number	US-201615083106-A
Country	US
Kind code	B2
Filing date	Mar 28, 2016
Priority date	Mar 27, 2015
Publication date	Oct 31, 2017
Grant date	Oct 31, 2017

Abstract

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

First claim

The invention claimed is:

1. A peptide consisting of the amino acid sequence of SEQ ID No. 11; or in the form of a pharmaceutically acceptable salt.

2. The peptide according to claim 1 , wherein the pharmaceutical acceptable salt is a chloride salt or acetate salt.

3. The peptide according to claim 1 , wherein said peptide is in the form of an acetate salt.

4. The peptide according to claim 1 , wherein said peptide is in the form of a chloride salt.

5. The peptide according to claim 1 , wherein said peptide is bound in an MHC complex.

6. A pharmaceutical composition comprising the peptide according to claim 1 and a pharmaceutically acceptable carrier.

7. The pharmaceutical composition according to claim 6 , wherein the pharmaceutically acceptable carrier is selected from the group consisting of saline, Ringer's solution and dextrose solution.

8. The pharmaceutical composition according to claim 6 , comprising additional pharmaceutically acceptable excipients and/or stabilizers.

9. The pharmaceutical composition according to claim 8 , wherein said additional pharmaceutically acceptable excipients are selected from the group consisting of buffers, binding agents, blasting agents, diluents, flavors, and lubricants.

10. A vaccine comprising the peptide of claim 1 .

11. A kit comprising the pharmaceutical composition according to claim 6 .

12. The kit according to claim 11 further comprising a second compound selected from the group consisting of an adjuvant, a chemotherapeutic agent, a natural product, a hormone or antagonist, an anti-angiogenesis agent or inhibitor, an apoptosis-inducing agent, a chelator, or a pharmaceutical composition thereof.

13. An artificial antigen presenting cell (aAPC) comprising an MHC complex comprising the peptide according to claim 1 on the surface of the aAPC.

14. A fusion protein comprising the peptide of claim 1 and the N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii).

Assignees

• Immatics Biotechnologies Gmbh

Inventors

• Mahr Andrea
• Weinschenk Toni
• Schoor Oliver
• Fritsche Jens
• Singh Harpreet
• Stevermann Lea

Classifications

• A61P39/00

  General protective or antinoxious agents · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P35/02

  specific for leukemia · CPC title

• G01N33/5758

  involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites · CPC title

• C07K14/47

  from mammals · CPC title